Vårdprogram för Urotelial urinblåsecancer 2000 - Medac

21. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al.
Maintenance Bacillus Calmette-Guèrin immunotherapy for recurrent Ta, T1 and
carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest
oncology group study. J Urol 2000; 163: 1124-29.
22. Månsson W, Davidsson T, Kristjansson A, Wullt B. Continent urinary diversion.
European Update Series 1994:3: 1-7.
23. Hellsten S, Rintala E, Wahlqvist R, Malmström P-U. Nordic prospective trials of radical
cystektomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer
Study Group. Eur Urol 1998;33(Suppl 4): 35-38.
23.Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with
transitional cell carcinoma of the urinary bladder; significance for staging and prognosis.
Br J Urol 2000; 85: 817-23.
24.American Society of Clinical Oncology. 2000 Educational Book, sidan 376-391. ASCO
Thirty-Six Annual Meeting, 2000.
25.Van der Maase H, Hansen SW, Roberts JT, Conte L et al. Gemcitabine and Cisplatin (GC)
versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin (MVAC) Chemotherapy in
Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium: A Large
Randomized Multicenter, Multinational Phase III Study. ASCO Thirty-Six Annual
Meeting, 2000, Abstract 1293.
26. Von der Maase H. An Overview of Gemcitabine + Cisplatin in Bladder Cancer. Treatment
of Solid Tumors: A Clinical Update of Gemzar® (Gemcitabine) and MTA (Multi-
Targeted Antifolate). Lily Oncology.
01-09-27
20